Galectin Therapeutics Inc. (GALT)

[biotech2010]

Technical indicators are out the window for GALT at this point in time, anyone who followed them is just plain dumb.

BofA raised their target for ICPT this morning to $872 from $81, that is a market cap of over $8B

GALT may have the best in class drug for this treatment since it showed a reversal of fibrosis in pre-clinical trials.

If they hit their Phase 1 goals (a slam dunk since they've already done in for Davanat) you would think their market cap should be at least 10% of ICPT's, or $800M-that would be about a $45 stock.

Any demonstration of efficacy, particularly reversal of fibrosis, and this stock is north of $100 overnight.